title: KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?
authors.forename: W
authors.initials: W
authors.lastname: Zhang
authors.forename: M J
authors.initials: MJ
authors.lastname: Labonte
authors.forename: H-J
authors.initials: HJ
authors.lastname: Lenz
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068818:Cetuximab; D003062:Codon; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D011905:Genes, ras; D006801:Humans; D009154:Mutation; D009362:Neoplasm Metastasis; D020641:Polymorphism, Single Nucleotide
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D003062:Codon; D000068818:Cetuximab